This method can also be used as an additional option for securing ovarian function, which reduces the risk of premature extinction of ovarian function and increases the number of pregnancies without affecting the safety of cancer therapy, regardless of the hormone receptor status of the cancer. This evidence concerns the gene NR4A1 and cancer.